# US 2013/0259853 A1 · Treatment of Acute Ischemic Stroke or Intracranial Bleeding with tPA and Carbamylated Erythropoietin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259853 A1
- Document ID: US20130259853A1
- Status: Published application
- Kind: A1
- Application number: 13/510,560
- Filed: 2010-11-15
- Published: 2013-10-03
- Earliest claimed: 2009-11-18
- Assignees: H. Lundbeck A/S
- Inventors: Thomas Nikolaj Sager; Michael Chopp; Zheng Gang Zhang
- Web page: https://patentgrep.com/patent/US20130259853A1

## CPC

- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method for treatment of intracranial bleeding in a patient in the need thereof comprising administration of a therapeutically effective amount tPa and a therapeutically effective amount of CEPO.

### Claim 10 (depends on 10)

The method according to claim 10, wherein the intracranial bleeding is due to treatment with tPa and/or due to an ischemic insult in the brain.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the dose of CEPO ranges from 0.5 μg/kg body weight to about 50 μg/kg body weight.

### Claim 12 (depends on 11)

The method according to claim 11, wherein tPa is administered at a dose of about 0.9 mg/kg body weight.

### Claim 13 (depends on 9)

The method according to claim 9, wherein the administration of tPa and CEPO is simultaneous, separate and/or sequential.

### Claim 14 (depends on 9)

The method according to claim 9, any wherein the carbamylated erythropoietin has the sequence of SEQ ID NO 1 or SEQ ID NO 2.

### Claim 15

A pharmaceutical composition comprising a therapeutically effective amount of CEPO and tPa and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the carrier is a diluent, an adjuvant or an excipient.

### Claim 17 (depends on 15)

A method of treating intracranial bleeding or acute ischemic stroke comprising administering the pharmaceutical composition of claim 15.

### Claim 18

(canceled)

### Claim 19 (depends on 9)

A kit comprising CEPO and tPa according to claim 9.

### Claim at position 13

20-26. (canceled)
